eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Lise Boussemart(Inserm), Stéphan Vagner(Institut Curie), Nigel Ribeiro(Centre National de la Recherche Scientifique), Christine Basmadjian(Centre National de la Recherche Scientifique), Frédéric Thuaud(Centre National de la Recherche Scientifique), Émilie Routier(Université Paris-Saclay), Alexander M.M. Eggermont(University Medical Center Utrecht), Gorana Tomasic, Hélène Malka-Mahieu(Université Paris-Sud), Oskar Hemmingsson(Centre National de la Recherche Scientifique), Laurent Désaubry(Centre National de la Recherche Scientifique), Nyam Kamsu-Kom(Inserm), Sandrine Agoussi(Inserm), Caroline Robert(Institut Gustave Roussy), Isabelle Girault(Inserm), Christina Mateus(Institut Gustave Roussy), Delphine Allard
Cited by 361
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k